Market Report, 223 Pages
Just Released – September 2021
Cord blood is the blood present in the umbilical cord and placenta after the delivery of a newborn. Before the birth of the baby, stem cells and immune cells are transferred from the mother to the fetus to boost the immune systems of the mother and baby in preparation for labor. At the time of delivery, the blood in the umbilical cord is a rich source of stem cells and other cells of the immune system. Today, companies known as cord blood banks are collecting, processing, and preserving umbilical cord blood and tissue, as well as an ever expanding range of newborn and adult stem cell types.
The potency of processed cord blood is measured using a total nucleated cell count (TNC). TNCs are stem cells and other cells of the immune system that protect the body. The predominant stem cell type present within cord blood is the hematopoietic stem cell (HSC). However, cord blood also contains mesenchymal stem cells (MSCs), a cell type that is abundant within umbilical cord tissue as well.
Treg cells are present in umbilical cord blood too. These are important cells because they have the potential to prevent GvHD during stem cell transplantation and improve autoimmune diseases, such as diabetes, rheumatoid arthritis, and multiple sclerosis. Finally, cord blood contains natural killer cells (NK cells), which are being programmed within clinical trials to target specific cancer cells.
Cord Blood and Tissue Banking
In many cases, banking of cord blood and cord tissue can confer health benefits to either the donor or the donor’s siblings due to partial or exact human leukocyte antigen (HLA) matching. HLA matching can reduce, and in some cases eliminate, serious medical complications such as graft-versus-host disease (GvHD) upon transplantation. Additionally, allogeneic (donor) cord blood and tissue products are immune advantaged, which can allow donor-recipient mismatches at some HLA loci to be well tolerated within transplantations and infusions.
Despite these advantages, a drawback of umbilical cord blood (UCB) transplantation is the low yield of hematopoietic stem and progenitor cells (HSCs) present in cord blood. Typically, a single unit of cord blood typically provides only enough cells for the treatment of children. To overcome this problem, transplanting physicians may use double UCB transplantations to increase the number of HSCs. However, double UBC transplantation leads to greater acquisition costs. Therefore, in recent years, the number of transplantations using UCB has been declining. Be The Match Registry in the U.S. started its supply of CBU’s for commercial transplantations in 2001 with 45 treatments. The number reached 1,178 in at its peak and then gradually it declined to 686 transplantations in 2018. This downward trend in utilization is concerning for the industry.
Nonetheless, cord blood has the potential to be an important source of therapeutic cells for a growing range of regenerative medicine applications. According to ClinicalTrials.gov, there are approximately 1,300 clinical trials evaluating the use of cord blood stem and progenitor cells. These studies use unmanipulated whole cord blood (total nucleated cells/TNC), mononuclear cells (MNC), or cord blood-derived mesenchymal stem cells (MSCs). These studies are targeting clinical indications that range from pulmonary diseases to infertility to orthopedic conditions, but the most common area of research is neurologic conditions—such as stroke, cerebral palsy, autism and hypoxic ischemic encephalopathy.
Global Cord Blood and Stem Cell Banking Market
For both therapeutic and financial reasons, the cord blood industry has been witnessing record levels of M&A activity in recent years, with market leaders gaining market share at the expense of smaller competitors and investors vying for buy-in opportunities. Novel pricing strategies, product cross-sells and upsells, and ingenious online and offline marketing strategies are being implemented by the industry’s market leaders. Meanwhile, new technologies to support ex vivo cord blood expansion are advancing at brisk pace
Today, more than 70% of the global cord blood market is controlled by the world’s 12 largest cord blood banking operators.
The reason for this is that massive cord blood industry consolidation has happened in recent years, particularly within the U.S, Europe, Asia, and Latin America. Important consolidation events within the industry have included
- Generate Life Sciences aggregating reproductive, newborn stem cell, and genetic services across the U.S., Canada, and Australia
- Cryoholdco aggregating stem cell banking assets within Latin America
- Sanpower Group dominating the Asian market
- Two leading cord blood brands (PBKM FamiCord and Vita34) consolidating the majority of the European market through aggressive M&A activity (and Cryo-Save AG going bankrupt)
India is another critical market that has surged in importance in recent years. This is because the country now boasts an astounding population of 1.4 billion, placing it head-to-head with China as the world’s most populous country. This means that an incredible one-third (36%) of the world’s 7.8 billion people live within India or China. Within India, LifeCell International is the market leader, with approximately 320,000 stem cell units in storage. Within China, Global Cord Blood Corporation (GCBC) controls the market share and is the only operator with multiple provincial licenses.
Within the United States, Generate Life Sciences controls Cord Blood Registry and its associated 900,000+ cord blood and tissue units in storage, as well as Natera’s Evercord™ cord blood and tissue banking business. It also owns cord blood banking assets in Australia (Cell Care) and Canada (Insception Lifebank and Cells for Life). Generate Life Sciences is a portfolio company of the private equity firm, GI Partners.
Within Australia, the largest cord blood bank, CellCare, had CPE Capital (CPEC) as its the majority investor for several years, but is now owned by Generate Life Sciences.
Within Asia, Sanpower Group is the dominant investment force. Headquartered in Nanjing, it is one of the largest private conglomerates in China, with investments across healthcare, retail and financial services. It has preserved over 900,000 cord blood samples in mainland China, and it has over 1.2 million units preserved when its Cordlife reserves within Southeast Asian countries are included. This positions Sanpower Group and its subsidiary Nanjing Cenbest as the largest cord blood banking operator within China and Southeast Asia.
Similar market consolidation and operational efficiency has been pursued within Europe, where the number of cord blood banks has dropped by more than one-third over the past decade, from approximately 150 to less than 100. The industry leaders in the European market include FamiCord Group, who has executed over a dozen M&A transactions in recent years, and Vita34, who has executed a half dozen. Stemlab, the largest cord blood bank in Portugal, also executed three acquisition deals prior to being acquired by FamiCord in August 2018 for $16.5 million. FamiCord is now the leading stem cell bank in Europe and one of the largest worldwide. FamiCord is controlled by Enterprise Investors.
For many years, CryoSave AG was a large cord blood banking operator who controlled several centralized processing facilities in Europe, India, and South Africa. It also operated numerous regional facilities through licensing agreements. But, in mid-2019, it entered the bankruptcy process and filed for liquidation. The brand name “CryoSave” and its client database (i.e., its storage contracts and sales database) were acquired by the company, CSG-BIO. Today, Cryo-Save’s umbilical cord blood units are stored by the Polish cord blood bank PBKM, part of the FamiCord network.
Within Latin America, ACON Investments is the major regional investor. It owns Cryoholdco as a portfolio company, which controls at least nine cord blood and dental pulp assets across the region and their associated 275,000 stem cell units in storage. Headquartered in Washington, DC, ACON Investments is a U.S. based investment fund that manages over $5.3 billion in assets.
Clearly, investor appetite for cord blood banks has never been stronger. This is because cord blood banks produce stable subscription revenue from long-term storage contracts. At a fundamental level, cord blood banks are both a real estate play (cryogenic storage facilities) and a regenerative medicine (RM) play.
Expansion of Cord Blood Banking Services
In addition to prolific industry consolidation and an aggressive M&A environment, a growing number of cord blood banks have been venturing into new types of stem cell storage, reproductive services, and related cell therapy applications. Specifically, cord blood, cord tissue, placental tissue, and dental pulp have demonstrated intriguing therapeutic promise, causing storage services for these biomaterials to proliferate.
Within the research realm, cord blood products (fresh and cryopreserved) are being offered by a diverse range of major market leaders, including Lonza, STEMCELL Technologies, AllCells, and dozens of others. Within the therapeutic realm, a growing number of companies are exploring the development and commercialization of perinatal products across a diverse range of applications.
Given the accelerating complexity and competitive nature of this global market, you don’t have the time to do the research. Claim the market report below to become immediately informed, without sacrificing hours of unnecessary research.
Recently released, the “Global Cord Blood Banking Industry Report” is a global strategic report that will position you to:
- Capitalize on emerging trends
- Improve internal decision-making
- Reduce company risk
- Approach outside partners and investors
- Implement an informed and advantageous business strategy in 2021
Cord Blood Report Highlights
This global strategic report presents a detailed market size determination, including a breakdown by geography, indication, and type of bank. It presents future projections for each market segment through 2027. It reveals the number of cord blood units stored in inventory by the largest cord blood banks worldwide, as well as the total storage count for both public and private units in storage worldwide. It also presents the number of cord blood units (CBUs) released by registries across the world for hematopoietic stem cell transplantation (HSCT).
It reveals the identities of companies offering cord blood storage, cord blood processing technologies, cord blood expansion technologies, and cord blood therapeutics on a global basis. Although cord blood is now used to treat 80 different diseases, this number will expand as regenerative medicine applications begin to receive approvals in major healthcare markets worldwide.
Overall, the report answers the following questions:
- Number of cord blood units cryopreserved in public and private cord blood banks globally
- Number of hematopoietic stem cell transplants (HSCTs) globally using cord blood cells
- Utilization of cord blood cells in clinical trials for developing regenerative medicines
- The decline of the utilization of cord blood cells in HSC transplantations since 2005
- Emerging technologies to influence financial sustainability of public cord blood banks
- The future scope for companion products from cord blood
- The changing landscape of cord blood cell banking market
- Extension of services by cord blood banks
- Types of cord blood banks
- Economic model of public cord blood banks
- Cost analysis for public cord blood banks
- Economic model of private cord blood banks
- Cost analysis for private cord blood banks
- Profit margins for private cord blood banks
- Pricing for processing and storage in private banks
- Rate per cord blood unit in the U.S. and Europe
- Indications for the use of cord blood-derived HSCs for transplantations
- Diseases targeted by cord blood-derived MSCs in regenerative medicine
- Cord blood processing technologies
- Number of clinical trials, number of published scientific papers and NIH funding for cord blood research
- Transplantation data from different cord blood registries
Key questions answered within the report are:
- What are the strategies being considered for improving the financial stability of public cord blood banks?
- What are the companion products proposed to be developed from cord blood?
- How much is being spent for processing and storing a unit of cord blood?
- How much does a unit of cryopreserved cord blood unit fetch on release?
- Why do most public cord blood banks incur a loss?
- What is the net profit margin for a private cord blood bank?
- What are the prices for processing and storage of cord blood in private cord blood banks?
- What are the rates per cord blood units in the U.S. and Europe?
- What are the revenues from cord blood sales for major cord blood banks?
- Which are the different accreditation systems for cord blood banks?
- What are the comparative merits of the various cord blood processing technologies?
- What is to be done to increase the rate of utilization of cord blood cells in transplantations?
- Which TNC counts are preferred for transplantation?
- What is the number of registered clinical trials using cord blood and cord tissue?
- How many clinical trials are involved in studying the expansion of cord blood cells in the laboratory?
- How many matching and mismatching transplantations using cord blood units are performed on an annual basis?
- What is the share of cord blood cells used for transplantation from 2000 to 2021?
- What is the likelihood of finding a matching allogeneic cord blood unit by ethnicity?
- Which are the top ten countries for donating cord blood?
- What are the diseases targeted by cord blood-derived MSCs in clinical trials?
VIEW TABLE OF CONTENTS: Global Cord Blood Banking Industry Report 2021
With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 15 years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capital Hill.
The content within this report was compiled using a diverse range of sources, as described in this Research Methodology. To select a License Type, click here.
Remember, all BioInformant products come with a Greater Than 100% Money Back Guarantee. If the strategies and tools aren’t helpful to you – we’ll cheerfully refund your money, and you can keep the product.
Have questions? Email us at [email protected] to get a rapid reply. Checkout below to get immediate access to this report, with printing rights allowed.